Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived stem cells (TCA Cellular Therapy)
- Development stage
- Unknown
- Lead developer
- TCA Cellular Therapy
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Autologous bone marrow-derived stem cells (BMSCs) developed by TCA Cellular Therapy are a type of cell therapy investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS). The therapy involves harvesting a patient's own bone marrow, isolating the stem cell fraction (which typically includes mesenchymal stem cells and other mononuclear cells), and re-administering them via intrathecal injection. The therapeutic rationale is primarily based on paracrine signaling, where the transplanted cells secrete various neurotrophic factors and anti-inflammatory cytokines. These factors, including BDNF, GDNF, and VEGF, aim to create a neuroprotective microenvironment that supports the survival of degenerating motor neurons and modulates neuroinflammation within the central nervous system. A Phase I clinical trial was conducted to evaluate the safety and preliminary efficacy of this approach in slowing disease progression in ALS patients.
- Other names
- BMSCautologous bone marrow-derived mesenchymal stem cellsintrathecal autologous bone marrow-derived stem cells
Beyond the preview
Go deeper on autologous bone marrow-derived stem cells (TCA Cellular Therapy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived stem cells (TCA Cellular Therapy).